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http:WHAT THIS PAPER ADDS
All-cause mortality and cardiac mortality in patients with asymptomatic carotid stenosis are very high. They
appear to remain high despite the reduction in mortality observed in the general population during the last 20
years. Although risk factors have been identiﬁed and risk stratiﬁcation is possible, most patients are classiﬁed as
high risk.Objective: Recent studies with asymptomatic carotid patients on best medical management have shown that the
annual risk of stroke has decreased to approximately 1%. There is no evidence that a similar decrease in mortality
has occurred. In addition, the intensity of statin therapy for these patients has not yet been determined. The aims
of this review were to determine (a) the reported long-term all-cause and cardiac-related mortality in patients
with asymptomatic carotid stenosis (ACS) > 50%, (b) whether there has been a decrease in mortality in recent
years, (c) the available methods of mortality risk stratiﬁcation, and (d) whether the latest ACC/AHA guidelines on
the treatment of serum lipids can be applied to this group of patients.
Methods: Systematic review of PubMed, EuroPubMed, and Cochrane Library and meta-analysis using random
effects for pooled proportions were performed regarding long-term all-cause and cardiac-related mortality and
the associated risk factors in ACS patients. The last day for literature search was October 30, 2014.
Results: Seventeen studies were retrieved reporting 5-year all-cause mortality in 11,391 patients with ACS >50%.
The 5-year cumulative all-cause mortality across all 17 studies was 23.6% (95% CI 20.50e26.80). Twelve
additional studies, reporting both all-cause and cardiac mortality with a minimum of 2 year follow-up and
involving 4,072 patients were identiﬁed. Of the 930 deaths reported, 589 (62.9%; 95% CI 58.81e66.89) were
cardiac-related. This translates into an average cardiac-related mortality of 2.9% per year.
Conclusions: All-cause and cardiac mortality in ACS patients are very high. Although risk stratiﬁcation is possible,
most patients are classiﬁed as high risk. In view of this high risk, aggressive statin therapy is indicated if the new
ACC/AHA guidelines on serum lipids are to be adhered to.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Two randomized controlled trials (RCTs), the Asymptomatic
Carotid Atherosclerosis Study (ACAS) in 19951 and the
Asymptomatic Carotid Surgery Trial (ACST) in 2004,2
recruited patients from 1988 to 2003, and reported that
574 A. Giannopoulos et al.carotid endarterectomy (CEA) reduced the risk of stroke
from about 2.0% to 1.0% per year in patients with asymp-
tomatic internal carotid artery (ACS) stenosis >60% in
relation to the distal internal carotid (NASCET criteria).1e3 In
these trials CEA was associated with a 2e3% 30-day peri-
operative risk of stroke or death. However, in these studies,
medical treatment and modiﬁcation of arterial disease risk
factors was left to the discretion of the local teams and was
suboptimal compared with current practice.
New and more effective medications have been intro-
duced since then, with guideline recommendations for
predeﬁned LDL-C and blood pressure (BP) targets for
symptomatic patients with atherosclerotic disease, but not
for patients with asymptomatic carotid stenosis.4,5
Recent reviews of cohort studies on the outcome of pa-
tients with ACS treated medically (including the medical
arms of randomized carotid endarterectomy trials) indicate
that the average annual risk of ipsilateral stroke has fallen to
approximately 1% or less.6e9 This is attributed to better
medical management including statin therapy; however,
there are no reports that a parallel decrease has occurred in
mortality including cardiac mortality.
The latest American College of Cardiology/American
Heart Association (ACC/AHA) guidelines on the treatment of
serum lipids state that for non-diabetic individuals aged
40e75 years without clinical evidence of atherosclerotic
cardiovascular disease (ASCVD) and an LDL-C of 70e
189 mg/dL (1.8e4.9 mmol/L), it is reasonable to prescribe
moderate intensity statins when the 10-year risk of devel-
oping “hard” ASCVD outcomes (ﬁrst fatal or non-fatal
myocardial infarction [MI], coronary artery disease [CAD]
death, fatal or non-fatal stroke) is 5e7.5%.10 In addition,
moderate or high intensity statins are recommended when
the 10-year risk of developing a ﬁrst “hard” ASCVD outcome
is >7.5%. Clinical ASCVD was deﬁned as acute coronary
syndromes, MI, angina, coronary or other revascularization,
stroke or TIA, or peripheral arterial disease (PAD) presumed
to be of atherosclerotic origin. These new guidelines which
rely on the 10-year risk of developing “hard” ASCVD out-
comes to determine the intensity of statin therapy have
prompted the current review.
The aims of this review were to determine (a) long-term
all-cause and cardiac-related mortality in patients with ACS
>50%, (b) whether there has been a decrease in mortality
in recent years, (c) the available methods of mortality risk
stratiﬁcation, and (d) whether, based on the currently re-
ported cardiac mortality, the latest ACC/AHA guidelines on
the treatment of serum lipids can be applied to this group
of patients.
METHODS
All-cause long-term mortality
The PubMed, EuroPubMed, and Cochrane databases were
searched for studies with late follow-up in patients with
medically or surgically treated ACS, independently by two of
the authors (AG and ANN). Any discrepancies were resolved
by discussion between the two authors. The (MeSH) searchterms were: “carotid” OR “CAS” OR “carotid stenting” OR
“carotid endarterectomy” or “CEA” AND “long-term mor-
tality” OR “late results” OR “5 year mortality” OR “10 year
mortality”. Identiﬁed studies were searched for relevant
publications in their reference lists. All clinical studies
reporting cumulative survivals at 5 or 10 years in patients
with ACS>50% (NASCET criteria) after medical or surgical
management were retrieved. Studies reporting outcomes in
patients with an asymptomatic carotid stenosis after
treatment of a contralateral symptomatic side were
excluded. Studies reporting total mortality in both symp-
tomatic and asymptomatic patients were accepted provided
the results were reported separately for these two groups
so that only the asymptomatic group could be included.
Studies identifying risk factors associated with increased
late mortality were also included in the analysis.
The results are reported as 5- or 10-year cumulative
mortality for each study and weighted cumulative mortality
for all studies based on meta-analysis. Average annual
mortality rates were calculated by dividing the 5- and 10-
year cumulative mortality by 5 or 10, respectively.Proportion of cardiac deaths
Because cardiac mortality was reported in only six of the
papers with 5- or 10-year follow-up using life table analysis,
a second search was performed of the same databases to
identify papers that reported the proportion of patients
that died from cardiovascular causes while reporting overall
mortality in patients with ACS >50% with a minimum of 2
years’ follow-up. Because lifetable analysis was not a cri-
terion for selecting such studies, a separate search became
necessary. The last day for both searches was October 30,
2014. This article was prepared in accordance with the
guidelines set out by the Preferred Reporting Items for
Systematic Review and Meta-analyses (PRISMA)
statement.11Pooling of data and regression according to date of
publication
Pooling of data was performed using meta-analysis using
random effects and associated tests for heterogeneity (Q
and I2) using Medcalc (version 15.4). A simple regression
was performed plotting 5-year cumulative mortality by year
of publication using SPSS version 20.
RESULTS
All-cause long-term mortality in patients with
asymptomatic carotid stenosis
One-hundred and twelve studies were identiﬁed evaluating
late mortality in patients with >50% internal carotid artery
(ICA) stenosis. Ninety studies were excluded because they
reported mortality results for <5 years or the results were
based on a mixture of asymptomatic and symptomatic pa-
tients. Five studies were rejected because the degree of
carotid stenosis was <50% or not reported at all. Finally, 17
studies remained (Fig. 1 and Table 1).12e28
314 records idenƟfied through  
PubMed, EuroPubMed and 
Cochrane database search 
23 addiƟonal records through 
other sources 
266 records aŌer duplicates 
removed 
166 of records screened 
reporƟng all-cause long-term 
mortality
17 studies included in the 
analysis 
112 full-text arƟcles assessed 
for eligibility 
95 full text arƟcles excluded for 
reporting mortality:  <5 years 
or  results based on a mixture 
of asymptomatic and 
symptomatic patients or on 
carotid stenosis  <50% (or not 
reported at all)
54 articles excluded as non full 
text articles
100 records excluded 
Figure 1. PRISMA 2009 ﬂow diagram: all-cause mortality.
Long-term Mortality in Patients with ACS 575Twelve of the studies listed in Table 1 reported all-cause
long-term mortality in asymptomatic patients after
CEA,12e14,16,18,20,21,23e27 and ﬁve after medical manage-
ment.15,17,19,22,28 The smallest study included 42 pa-
tients,14 and the largest one, 4,114.26 Eleven studies
reported 5-year mortality only. Six studies provided both
5- and 10-year mortality. Five studies included patients
with a carotid stenosis >50%, two studies included pa-
tients with 50e79% stenosis only, three with >60%, and
seven with >70%. In four studies25e28 published in 2013
and 2014, most patients were on statins, but there was no
information on whether treatment was to a predeﬁned
target. It is not mentioned whether patients were treated
with statins in the older studies.
The mean baseline age of patients in different studies
ranged from 61 to 74.5 years, 51e100% were males, 43e
89% hypertensive, 15e38% diabetic, and 18e64% had a
history of CAD or MI (epidemiological data reported in 10
out of the 17 above studies). Of the patients, 21e80% were
smokers/ex-smokers (data in 9 from the above studies),
37e54.2% were hyperlipidemic (data in 5 from the above
studies), and 33e60% were found to have PAD (data
derived from 5 out of 17 studies).
The 5-year weighted average cumulative all-cause mor-
tality across all 17 studies involving 11,391 patients was23.6% (95% CI 20.50e26.80) (Table 1 and Fig. 2) (average
annual mortality 4.6%). In the ﬁve studies in which patients
(n ¼ 944) did not have a CEA, the 5-year weighted average
cumulative all-cause mortality was 24.35% (95% CI 21.65e
27.21). In the remaining studies in which patients
(n ¼ 10,447) had a CEA before follow-up, the 5-year
weighted average cumulative all-cause mortality was
22.7% (95% CI 22.96e23.59).
The lowest 5-year cumulative all-cause mortality of 10%
was reported in the subgroup of women reported sepa-
rately from men in the study by Mattos et al. in 2001.21 The
highest mortality, 37%, was found in two studies (Cohen
et al. in 1993 and Mansour et al. in 1995).16,17
In the seven studies reporting both 5- and 10-year cu-
mulative mortality involving 3,297 patients, the weighted
average cumulative all-cause mortalities were 25.8% (95%
CI 24.35e27.36) (average annual mortality of 5.2%) and
52.4% (95% CI 50.65e54.08) (average annual mortality of
5.2%), respectively.
The 5-year all-cause cumulative mortality from the
studies listed in Table 1 was plotted against the year of
publication (Fig. 3). There was no statistically signiﬁcant
reduction in mortality during the last 30 years (1985e2014).
Exclusion of any single study from the meta-analysis did
not substantially alter the overall result of the meta-analysis
Table 1. All-cause mortality in patients with >50% diameter (NASCET) asymptomatic carotid stenosis (ACS).
Author n %
Stenosis
CEA 5-year
cumulative
mortality
10-year
cumulative
mortality
Average
annual
mortality
in years 1e5
Average
annual
mortality
in years 1e10
Risk stratiﬁcation
for mortality
Risk
factors
identiﬁed
Statin therapy
Moore et al., 198512 76 >50% þ 35% e 7.0% e Severity of
stenosis
Yes e
Hertzer and Arison, 198513 126 >50% þ 26% 56% 5.2% 5.4% Using suspected
myoc. ischemia
Yes e
Rosenthal et al., 198714 42 >50% þ 24% 53% 4.8% 5.3% No No e
Bernstein et al., 199215 180 >50%  18% e 3.6% e No Yes e
Cohen et al., 199316 211 >50% þ 37% e 9.4% e Using risk factors Yes e
Mansour et al., 199517 142 50e79%  37% e 9.4% e No No e
Branchereau et al., 199818 357 >70% þ 25% 41% 5.0% 4.1% Using associated
vascular disease
No e
Rockman et al., 199719 425 50e79%  23% e 4.6% e No No e
Cao et al., 1999 (SBI þ)20 103 >60% þ 18% 39% 3.6% 3.9% Using SBI þ or  No e
Cao et al., 1999 (SBI )20 198 >60% þ 14% 31% 2.8% 3.1% Using SBI þ or  No e
Mattos et al., 200121 (Men) 247 60e99% þ 15% e 3.0% e Yes Yes e
Mattos et al., 200121 (Women) 154 60e99% þ 10% e 2.0% e Yes Yes e
AbuRahma et al., 200322 82 60e69%  17% 33% 3.4% 3.3% No No e
Reed et al., 200323 639 >70% þ 28% e 5.6% e e e e
Kragsterman et al., 200624 631 >70% þ 22% 55% 4.4% 5.5% No Yes e
Conrad et al., 201325 1791 >70% þ 27% e 5.4% e Conventional
risk factors
Yes Some patients
Wallaert et al., 201326 4114 >70% þ 18% e 3.6% e Conventional
risk factors
Yes Some patients
Kang et al., 201427 1758 >70% þ 30% 58% 6.0% 5.8% Conventional
risk factors
Yes Some patients
Conrad et al., 201428 115 >70%  30% e 6% e Using risk factors Yes Some patients
SBI ¼ silent brain infarcts.
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Table 2. Prevalence of all-cause and cardiac-related mortality in
930 patients with >50% diameter (NASCET) asymptomatic
carotid stenosis (ACS) who died during follow-up.
Author Patients,
n
Mean
follow-up,
months
All
deaths,
n
Heart-related
deaths, n
Chambers
et al., 198629
113 23 21 12 (57%)
Hertzer
et al., 198513
126 Up to
10 years
72 38 (53%)
Rosenthal
et al., 198714
42 120 16 10 (62%)
Meissner
et al., 198730
292 39 75 48 (64%)
Moneta
et al., 198731
115 Up to 48 19 8 (42%)
Cohen
et al., 199316
444 48 164 100 (61%)
Mansour
et al., 199517
144 60 20 14 (70%)
Cao
et al., 199920
301 67.3 53 32 (60%)
Mattos
et al., 200121
241,
men only
50 38 31 (82%)
AbuRahma
et al., 200322
88 59.5 15 10 (67%)
Kakkos
et al., 200532
1,101 38 162 104 (64%)
Goliasch
et al., 201233
1,065 74 275 182 (66%)
Figure 2. Forest plot of studies listed in Table 1 showing the
weighted average (random effects) 5-year all-cause mortality. (Test
for heterogeneity: Q ¼ 221; DF 18; p < .0001; I2 ¼ 91.9%; 95% CI
for I2 88.7e94.1).
Long-term Mortality in Patients with ACS 577in terms of proportion and variability. In addition, limiting
the meta-analysis to the large studies published after 2002
produced similar results (Total Random effects proportion:
24.5% [95% CI 19.89e29.52]; Q ¼ 135.7; DF ¼ 6; p < .0001;
I2 95.58).
Proportion of cardiac deaths
Sixty-ﬁve studies analyzing the causes of death in patients
with ACS irrespective of duration of follow-up were identi-
ﬁed. Forty-ﬁve studies were excluded because the follow-up
was <2 years or the results were based on mixed cohorts ofFigure 3. Five-year all-cause cumulative mortality from studies
listed in Table 1 plotted against year of publication. Open circles
represent studies with follow-up of patients without carotid end-
arterectomy and closed circles represent studies with follow-up
after carotid endarterectomy (Linear regression is not signiﬁcant:
Pearson correlation e 0.154; p ¼ .530).symptomatic and asymptomatic patients. Eight studies
were rejected because they did not mention the degree of
stenosis or this was <50%. As a result, 12 studies remained
with follow-up >2 years in a total of 4,072 patients (Table 2
and Fig. 4).13,14,16,17,20e22,29e33 The sample size ranged from
42 to 1,101 patients. There were 930 deaths, of which 589
were cardiac-related. The percentage of cardiac mortality in
those who died in the different studies varied between 42%
and 82% with a weighted average of 62.8% (95% CI 58.8e
66.9) (Fig. 5). This translates into an average cardiac-related
mortality of 2.9% per year.Risk factors associated with increased all-cause mortality
in ACS patients and stratiﬁcation into different risk groups
for death
Among the 112 studies that were initially retrieved, eight
reported on risk factors and hazard ratios (HR) associated
with increased all-cause late mortality using univariate an-
alyses (Table 3).16,20,24e28,33 Identiﬁed risk factors were:
age, diabetes, smoking, CAD, abnormal ECG, congestive
heart failure (CHF), chronic obstructive pulmonary disease
(COPD), impaired renal function, lack of statin therapy,
contralateral internal carotid stenosis or occlusion, inter-
mittent claudication, lacunar infarcts, high risk for surgery,
and history of previous vascular surgery.
Multivariable regression analysis with all-cause mortality
as the dependent variable was performed in only ﬁve
studies,16,23,26e28 and stratiﬁcation into different all-cause
290 records idenƟfied through 
PubMed, EuroPubMed and 
Cochrane database search 
6 addiƟonal records through 
other sources 
175 records aŌer duplicates 
removed 
74 of records screened reporƟng 
cardiac-related mortality
12 studies included in the 
analysis 
65 full-text arƟcles assessed for 
eligibility 
53  full text arƟcles excluded for 
reporting cardiac-related 
mortality:  <2 years or  results 
based on a mixture of 
asymptomatic and 
symptomatic patients or on 
carotid stenosis  <50% (or not 
reported at all)
9 articles excluded as non full 
text articles
101 records excluded
Figure 4. PRISMA 2009 ﬂow diagram 2: cardiac-related mortality.
578 A. Giannopoulos et al.mortality risk groups using independent predictors was
made in three of these16,23,26 (Table 4).
In the study by Cohen et al.16 published in 1993, three
risk factors were independent predictors of death: diabetes,Figure 5. Forest plot of studies listed in Table 2 showing the
proportion of cardiac deaths in those that died. (Test for hetero-
geneity: Q ¼ 15.3; DF 11; P ¼ 0.167; I2 ¼ 28.3%; 95% CI for I2 0.00
to 63.7-random effects).abnormal ECG results, and intermittent claudication. In the
absence of any of these risk factors, annual mortality was
5.5%. In the presence of one, two, or three factors, it was
7.5, 11.3 and 13.3%, respectively (Table 4).
In the study by Reed et al.23 published in 2003, signiﬁcant
risk factors consisted of coronary bypass within 6 months,
CHF, COPD, creatinine 2.0 mg/dL (176.8 mmol/L),
contralateral carotid occlusion, and age >80 years. In the
absence of any of these risk factors, annual mortality was
5.6%. In the presence of one, two or more factors and
contralateral carotid occlusion, annual mortality was 10.2,
10.6, and 13.2%, respectively (Table 4).
In the study by Wallaert et al.26 published in 2013, three
risk groups were established. Each covariate in the predic-
tion model was classiﬁed as either a major or minor risk
factor for mortality based on its relative contribution to the
ﬁnal regression equation. Four major risk factors were
identiﬁed: age >80 years, insulin-dependent diabetes,
dialysis dependence, and contralateral ICA stenosis 80e
99%. Minor risk factors included age 70e80 years,
noninsulin-dependent diabetes, smoking history, CHF,
COPD, estimated glomerular ﬁltration rate<60 ml/min, lack
of statin therapy, contralateral ICA stenosis 50e80%, and
Table 3. Risk factors and hazard ratios associated with all-cause mortality rates in patients with >50% diameter (NASCET) asymptomatic
carotid stenosis (ACS) who died during follow-up.
Risk factors Mortality hazard ratio Studies
Age 1.5e1.8 Conrad et al., 2013,25 Goliasch et al., 2012,33
Conrad et al., 201428
Age>70 years 2.2 Cao et al., 199920
Age 70e79 years 1.8 Wallaert et al., 201326
Age >80 years 3.94 Wallaert et al., 201326
Diabetes 1.63e2.3 Cao et al., 1999,20 Kragsterman et al., 2006,24
Conrad et al., 2013,25 Cohen et al., 1993,16 Kang
et al., 2014,27 Conrad et al., 201428
Diabetes þ oral medication 1.34 Wallaert et al., 201326
Diabetes þ insulin 1.98 Wallaert et al., 201326
COPD (chronic obstructive pulmonary disease) 1.66e5.08 Conrad et al., 2013,25 Wallaert et al., 2013,26
Kang et al., 2014,27 Conrad et al., 201428
Cardiac disease 1.5e1.78 Kragsterman et al., 2006,24 Conrad et al., 2013,25
Cohen et al., 1993,16 Wallaert et al., 201326
No use of statin 1.27e2.1 Conrad et al., 2013,25 Wallaert et al., 201326
Smoking 1.68 Wallaert et al., 201326
Creatinine >1.5 mg/dL 2.6 Conrad et al., 201325
eGFR<60 mL/min 1.3 Wallaert et al., 201326
Dialysis 3.41 Wallaert et al., 201326
Lacunar infarcts 1.9 Cao et al., 199920
Contralateral stenosis 50e80% 1.23 Wallaert et al., 201326
Contralateral stenosis 80e99% 1.9 Wallaert et al., 201326
Contralateral occlusion 1.69 Wallaert et al., 201326
Previous vascular surgery 1.8 Kragsterman et al., 200624
Claudication 1.68 Cohen et al., 199920
Coronary artery disease 1.42 Kang et al., 201427
Female gender 0.89 Kang et al., 201427
Lipid lowering agents 0.69 Kang et al., 201427
High risk for surgery 2.51 Conrad et al., 201428
Long-term Mortality in Patients with ACS 579contralateral ICA occlusion. The high-risk group included
patients with three major or two major plus two or more
minor risk factors (Table 4). Patients with one major plus
less than three minor risk factors were classiﬁed as medium
risk, and patients with less than two minor risk factors as
low risk. The annual mortality rate was 1.2% in the low-risk
group (27% of the patients), 4.0% in the moderate-risk
group (65% of the patients), and 9.8% in the high-risk
group (5% of the patients) (Table 4). In this study, 80% of
the patients were on statin therapy, but there is no indi-
cation whether treatment was to a pre-speciﬁed target.
In the two most recent studies, published in 2014, a Cox
proportional hazards regression model was used to identify
the independent predictors of risk. In the Kang et al.
study,27 COPD (HR 1.60, 95% CI 1.42e1.82), diabetes (HR
1.60; 95% CI 1.44e1.77), and CAD (HR 1.42; 95% CI 1.29eTable 4. Annual all-cause mortality in low-, moderate-, and high-risk gr
was performed.
Author n Low-risk group Moderate
% Of
cohort
Annual
mortality
% Of
cohort
Cohen et al., 199316 211 15% 5.5% 37%
Reed et al., 200323 1184 45% 5.0% 36%
Wallaert et al., 201326,a 4114 27% 1.2% 65%
a 80% of patients were on statins.1.56) were associated with increased mortality. Female
gender (HR 0.89; 95% CI 0.81e0.98) and lipid lowering
therapy (HR 0.69; 95% CI 0.63e0.76) were protective. In the
Conrad et al. study,28 age (per year; HR 1.06; 95% CI 1.03e
1.1), COPD (HR 1.92; 95% CI 1.08e3.41), diabetes (HR 5.08;
95% CI 2.86e9.01), and high risk for surgery (HR 2.51; 95%
CI 1.44e4.41) were multivariate predictors of death. How-
ever, the authors did not report stratiﬁcation into different
risk groups.DISCUSSION
The results of this systematic review and meta-analysis
indicate that in patients with >50% ACS, 5- and 10-year
all-cause mortality was 23% and 52.5%, respectively.
Nearly two thirds (63%) of the deaths were cardiac-related,oups of ACS patients in studies in which mortality risk stratiﬁcation
-risk group High-risk group Very high-risk group
Annual
mortality
% Of
cohort
Annual
mortality
% Of
cohort
Annual
mortality
7.5% 36% 11.3% 12% 13.3%
6.6% 14% 12.2% 6% 13.4%
4.0% 5% 9.8% e e
580 A. Giannopoulos et al.mainly MI or CHF subsequent to ischemic episodes. This
translates to a 10-year risk of cardiac-associated mortality of
33% (average annual cardiac mortality of 3.3%).
The data also show that the 10 year all-cause mortality is
double the 5-year all-cause mortality, indicating that the
rate of death is the same throughout the 10-year period
(average annual mortality of 5.2% for both the ﬁrst and
second 5-year periods).
Epidemiological studies such as Framingham and the
Prospective Cardiovascular Munster Study (PROCAM)34
classify asymptomatic populations into low-, intermediate-
, and high-risk groups for cardiovascular events (stroke, MI
and fatal stroke or MI). These risk groups are deﬁned ac-
cording to whether the 10-year risk is <10% (<1.0% per
year), 10e20% (1.0e2.0% per year), or >20% (>2% per
year), respectively. Using this classiﬁcation as a reference,
patients with >50% ACS are at extremely high risk.
For the age group of 65e74, which corresponds to the
age group of patients in the studies listed in Table 1, the risk
of death at 1 year for male individuals of the general
population in England and Wales is one in 6035 based on
mortality statistics of 2005.36 This translates into an annual
mortality of 1.67%, a 5-year mortality of 8.33% and a 10-
year mortality of 16.7%. Thus, the 5-year all-cause mortal-
ity of 23% shown by the meta-analysis in patients with ACS
is three times higher than the mortality for the general
population of the same age.
In the year 2000, CAD accounted for 25% of all deaths for
age groups 60e69 and 70e79 in the UK. In the year 2010,
CAD accounted for 18% for age group 60e69 and 21% for
age group 70e79.37 These national statistics indicate that
the deaths from CAD in patients with ACS found in this
meta-analysis are three times higher than the general
population of the same age.
In addition, this meta-analysis suggests that the high
mortality in patients with ACS has not declined during the
last 30 years, despite a decline in annual stroke rates. Fig. 4
shows a trend which is not statistically signiﬁcant. This is in
contrast with the decline in both all-cause mortality by 45%
and CAD mortality by 30% observed in the UK general
population of the same age during the period of 1990e
2010.37
Only the four most recently published studies,25e28
mentioned that a proportion of patients were on statins,
but there is no information about whether these patients
were treated to a pre-speciﬁed LDL-C target. It is also not
clear whether patients were treated with statins in the rest
of the publications included in this review and published
prior to 2007.
In the present review, only three studies were identiﬁed
that proposed scoring systems for better risk stratiﬁcation
of patients with ACS. Annual mortality of 1.2% per year was
found in the low-risk subgroup consisting of 27% of the
patients of one study26 (Table 4). It included patients
without any risk factors and most were taking statins. In all
the other subgroups, patients had a mortality 4.0% per
year. In terms of cardiac mortality this ﬁgure translates into
2.7% per year or more.The 2013 ACC/AHA guidelines recommend that non-
diabetic individuals without clinical (i.e. symptomatic)
ASCVD and an LDL-C of 70e189 mg/dL (1.8e4.9 mmol/L)
should be treated aggressively with statins in addition to
other risk factor modiﬁcations when the 10-year risk of
ASCVD is >7.5% (average annual risk >0.75%). The ratio-
nale provided by the ACC/AHA Expert Panel for this
approach is as follows.10 RCTs show that ASCVD events are
reduced by using the maximum tolerated statin intensity in
those groups shown to derive beneﬁt. For asymptomatic
patients (primary prevention) RCTs have shown that for
those with LDL-C levels of 70e189 mg/dL (1.8e4.9 mmol/L)
and a 10-year risk of ASCVD >7.5% (average annual
risk > 0.75%), statin therapy produces a substantial
reduction not only in non-fatal ASCVD events but also in
total mortality.38,39 In the Cochrane meta-analysis of 14
RCTs of statin therapy in primary prevention, statins were
associated with a 28% reduction in fatal and non-fatal CAD
events (RR 0.72; 95% CI 0.65e0.79), a 22% reduction in
fatal and non-fatal stroke (RR 0.78; 95% CI 0.65e0.94), and
a 17% reduction in overall mortality (RR 0.83; 95% CI 0.73e
0.95).39 In addition, the absolute beneﬁt was found to be
higher in those at higher baseline risk.
The 2013 ACC/AHA guidelines10 deﬁne intensity of
statin therapy on the basis of the average expected LDL-C
reduction. High-intensity statin therapy lowers LDL-C
by  50%, moderate-intensity by 30-<50%, and low-
intensity by <30%. There is high-level evidence from
RCTs that high-intensity therapy is achieved with atorvas-
tatin 40e80 mg daily or rosuvastatin of at least 20 mg, and
that high-intensity therapy reduces the ASCVD risk more
than moderate-intensity therapy achieved with atorvasta-
tin 10 mg, pravastatin 40 mg, or simvastatin 20e40 mg
daily.10
On the basis of the high cardiac-related mortality and the
2013 ACC/AHA guidelines it seems appropriate that all pa-
tients with ACS >50% should receive high-intensity statin
therapy, because even the lowest identiﬁable risk group has
an annual risk >0.75%.
Screening for ACS in the past was based on the belief that
it was possible to prevent strokes by operating or stenting
most moderate to severe stenotic lesions. This practice, a
legacy of the ACAS1 and ACST2 is now outmoded.40 With a
current annual stroke risk of 1%, this practice is likely to
produce more strokes than it can prevent,6,41 unless it be-
comes possible to identify the minority of patients at high
risk (>2% per year) for ipsilateral stroke42e44 despite
optimal medical therapy.
Currently, the ﬁnding of an ACS >50% (or even athero-
sclerotic plaques producing ACS <50%) carries a new
message.45 It identiﬁes individuals at high risk for all
atherosclerotic arterial disease manifestations, including
CAD-related mortality, who may then beneﬁt from high-
intensity statin therapy according to current guidelines for
high-risk individuals.
A limitation of the present review is that CEA was per-
formed in most studies prior to follow-up, with only ﬁve
studies on medical therapy alone. However, a separate
Long-term Mortality in Patients with ACS 581meta-analysis performed in these two groups of studies
demonstrated similar 5-year mortality rates.
A second limitation of this review is that there is limited
information on statin therapy, and many confounding fac-
tors such as other medications, smoking, and diabetes were
not available in many of the studies retrieved so adjust-
ments could not be made for them. The various con-
founding factors and selection of patients in the different
studies may be responsible for the heterogeneity on the
mortality reported. However, despite this heterogeneity, the
5-year all-cause mortality is high in almost all patients
(Table 4).
A third limitation on the appropriateness of the available
guidelines for patients with ACS >50% is that their con-
clusions are based on RCTs evaluating the efﬁcacy of statins
in asymptomatic individuals at high cardiovascular risk
irrespective of the presence or absence of ACS >50%. The
only criterion available for applying the new guidelines to
patients with ACS is the high cardiac risk.
For absolute values of cardiac events in patients with ACS
on “best” medical treatment, the results of future pro-
spective cohort studies are awaited, such as ACSRS-OMT
(Asymptomatic Carotid Stenosis and Risk of Stroke e
Optimal Medical Therapy) or medical arms of randomized
studies such as CREST (Carotid Revascularization Endarter-
ectomy versus Stenting Trial). These values will depend on
just how intensive the medical therapy will be and how well
coexisting silent preclinical CAD is investigated and treated.
CONCLUSIONS
All-cause mortality and cardiac mortality in patients with
ACS are very high. They appear to remain high despite the
reduction observed in the general population during the
last 20 years. Although risk factors have been identiﬁed and
risk stratiﬁcation is possible, most patients are classiﬁed as
high risk. In view of this high risk, aggressive statin therapy
is indicated if the new ACC/AHA guidelines on serum lipids
are to be adhered to.
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